Verenium Corporation
 | |
| Public Company (NASDAQ: VRNM) | |
| Industry | Industrial Biotechnology |
| Founded | 2007 |
| Headquarters | San Diego, California |
Key people | James Levine (President & CEO), Janet Roemer (COO), Jeff Black (CFO) |
| Products | Enzymes |
Number of employees | 130 |
| Website | www.verenium.com |
Verenium Corporation is a San Diego, California-based industrial biotechnology company that specializes in the development of high performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries including the global food and fuel markets.
Using proprietary and patented genomic technologies, Verenium extracts microbial DNA directly from collected samples to avoid the slow and often impossible task of growing microbes in the laboratory. Verenium then mines its collection of microbial genes, numbering in the billions, using high-throughput screening technologies designed to identify unique enzymes as product candidates. As required, these enzymes can then be further optimized for commercial use through the Company's patented DirectEvolution® technologies. By combining discovery and laboratory evolution technologies, Verenium has successfully developed and commercialized a suite of highly differentiated enzyme products tailored to meet the specific needs of companies in various markets, including grain processing, biofuels, animal health and nutrition and other industries.
On September 20, 2013, Verenium entered an agreement to be acquired by BASF.[1]
See also
References
- ↑ "BASF announces cash offer to acquire specialized enzyme biotechnology company Verenium". BASF. 20 September 2013. Retrieved 21 September 2013.